Form 4: AI Day1 LLC Exits Day One Biopharmaceuticals Position

AI Day1 LLC and affiliated entities have disposed of their entire stake in Day One Biopharmaceuticals following a successful tender offer and merger.

Summary

• AI Day1 LLC, controlled by Len Blavatnik, has exited its position in Day One Biopharmaceuticals (DAWN).
• The exit was triggered by a tender offer from Servier Detroit Inc. to acquire all outstanding shares for $21.50 per share in cash.
• AI Day1 LLC tendered 12,929,322 shares of common stock and converted 827,586 pre-funded warrants into cash at $21.4999 per warrant.
• The transaction was finalized on April 23, 2026, following the consummation of the merger.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced merger and the subsequent exit of a major shareholder.

Positives

• Successful liquidity event for major shareholders at a fixed cash price of $21.50 per share.
• Full divestment of equity holdings indicates a clean exit from the issuer.

Negatives

• The reporting entity no longer holds any beneficial ownership in Day One Biopharmaceuticals.

Risks

• None, as the reporting entity has fully divested its interest in the issuer.

Future Outlook

No future outlook provided as the reporting entity has fully divested its interest in the issuer.

Industry Context

StockSavvy.ai notes that this filing confirms the completion of the acquisition of Day One Biopharmaceuticals by Servier, reflecting ongoing consolidation trends within the biopharmaceutical sector where larger entities acquire specialized firms to bolster their clinical pipelines.

Comparison to Industry Standards

• The acquisition price of $21.50 per share represents a standard exit strategy for institutional investors in the biotech space.
• The use of a tender offer followed by a merger is a common mechanism for public company acquisitions in the U.S. market.

Stakeholder Impact

• Shareholders have received cash consideration for their equity as part of the acquisition.

Next Steps

• None, as the reporting entity has zeroed out its holdings.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Merger, Tender Offer, AI Day1 LLC, Len Blavatnik, Divestment